+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Urothelial Carcinoma - Epidemiology Forecast to 2028

  • ID: 4845139
  • Report
  • September 2019
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 2
‘Urothelial Carcinoma- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of urothelial carcinoma in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:2017-2028

Urothelial Carcinoma Epidemiology

The Urothelial Carcinoma epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for urothelial carcinoma are studied through all possible division to give a better understanding of the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Urothelial Carcinoma Epidemiology Segmentation

The Report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by:
  • Diagnosed Incident Population of Urothelial Carcinoma
  • Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma
  • Severity-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Age-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Gender-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Tumor (T) stage-specific Diagnosed Incident Population of Urothelial Carcinoma
  • Metastatic stage-specific Diagnosed Incident Population of Urothelial Carcinoma
According to this report, the total diagnosed incident cases of Urothelial Carcinoma in the seven major markets were 243,151, out of which the total cases of locally advanced/metastatic Urothelial Carcinoma were 96,711 cases in 2017.

Report Scope
  • The report covers the detailed overview of urothelial carcinoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of urothelial carcinoma.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type-specific cases and severity specific cases of urothelial carcinoma in the 7MM.
Key Strengths
  • 10-Year Forecast of urothelial carcinoma epidemiology
  • 7MM Coverage
  • Total Incident Cases of urothelial carcinoma
  • Incident Cases according to segmentation
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2

1. Key Insights

2. Disease Background and Overview: Urothelial Carcinoma (UC)
2.1. Introduction
2.2. Grading of Urothelial carcinoma
2.2.1. G1 tumors
2.2.2. G3 tumors
2.2.3. G2 tumors
2.3 Histological Features of Urothelial Neoplasm
2.3.1 Papillary urothelial neoplasm of low malignant potential (PUNLMP)
2.3.2 Low-grade papillary urothelial carcinoma
2.3.3 High-grade papillary urothelial carcinoma
2.4 TNM Staging System
2.4.1 Stages of urothelial carcinoma
2.5 Classification for Urothelial Carcinoma
2.5.1. Non-invasive inverted urothelial neoplasms
2.5.2. Urothelial dysplasia and carcinoma in situ with "early papillary formation"
2.5.3. Morphologic spectrum of inverted urothelial neoplasms
2.5.4. Invasive urothelial carcinoma
2.6 Risk factors for Urothelial Neoplasm
2.6.1 Cigarette smoke
2.6.2 Analgesics
2.6.3 Genetic effects
2.6.4 Occupational carcinogen exposure
2.7 Pathogenesis for Urothelial Neoplasm
2.8 Molecular pathogenesis and prognostics of bladder cancer for Urothelial carcinoma
2.8.1 The molecular basis of multifocality of urothelial tumors
2.8.2 Urothelial carcinoma phenotypes and their behavior
2.8.3 Molecular classification of urothelial carcinoma
2.8.4 Molecular classification of urothelial carcinoma
2.9 Biomarkers for Urothelial carcinoma
2.9.1 Proteomic and peptidomic analysis
2.9.2 Protein Biomarkers
2.9.3 Transcriptomic Biomarkers
2.9.4 Epigenetic DNA Methylation Markers
2.9.5 cfDNA, mutation, and microsatellite alterations
2.9.6 Urinary tumor RNA
2.9.7 Messenger RNAs (mRNAs) and Transfer RNA fragments (tRFs)
2.9.8 Extracellular vesicles (EVs) and exosomes
2.10 Diagnosis for Urothelial carcinoma
2.10.1 Aura Tek FDP Test
2.10.2 Cystoscopy and Cytology
2.10.3 BTA stat and BTA TRAK
2.10.4 NMP22 BC Test and NMP22 BladderChek Test
2.10.5 ImmunoCyt/uCyt
2.10.6 UroVysion
2.10.7 CertNDx
2.10.8 Cxbladder test
2.10.9 Cytologic-based tests
2.10.10 Urine cytology and FISH
2.10.11 Imaging
2.10.12 Photodynamic diagnosis (PDD)
2.10.13 Endoscopy
2.10.14 New upcoming technologies for diagnosis
2.10.15 Urothelial Carcinoma in Nutshell

3 Diagnostic Guidelines: American Urology Association (AUA)
3.1 Risk Stratification
3.1.1 Variant Histology
3.1.2 Urine marker after diagnosis of bladder Cancer
3.1.3 TURBT/Repeat Resection: Timing, Technique, Goal, Indication
3.1.4 Intravesical Therapy; BCG/Maintenance; Chemotherapy/BCG Combinations
3.1.5 BCG Relapse and Salvage Regimen

4 Epidemiology and Patient Population
4.1 Key Findings
4.2 7MM Total Diagnosed Incident Patient Population of Urothelial Carcinoma

5 Country Wise-Epidemiology of Urothelial Carcinoma
5.1 United States
5.1.1 Assumptions and Rationale
5.1.2 Urothelial Carcinoma Diagnosed Incident Population in the United States
5.1.3 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United States
5.1.4 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United States
5.1.5 Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United States
5.1.6 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United States
5.1.7 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United States
5.1.8 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United States
5.2 EU5 Countries
5.2.1 Assumptions and Rationale
5.3 Germany
5.3.1 Diagnosed Incident Population in Germany
5.3.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Germany
5.3.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Germany
5.3.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Germany
5.3.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Germany
5.3.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Germany
5.3.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Germany
5.4 France
5.4.1 Urothelial Carcinoma Diagnosed Incident Population in France
5.4.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in France
5.4.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in France
5.4.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in France
5.4.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in France
5.4.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in France
5.4.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in France
5.5 Italy
5.5.1 Urothelial Carcinoma Diagnosed Incident Population in Italy
5.5.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Italy
5.5.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Italy
5.5.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Italy
5.5.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Italy
5.5.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Italy
5.5.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Italy
5.6 Spain
5.6.1 Urothelial Carcinoma Diagnosed Incident Population in Spain
5.6.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Spain
5.6.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Spain
5.6.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Spain
5.6.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Spain
5.6.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Spain
5.6.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Spain
5.7 United Kingdom
5.7.1 Urothelial Carcinoma Diagnosed Incident Population in the United Kingdom
5.7.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United Kingdom
5.7.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United Kingdom
5.7.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United Kingdom
5.7.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United Kingdom
5.7.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United Kingdom
5.7.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United Kingdom
5.8 Japan
5.8.1 Assumptions and Rationale
5.8.2 Urothelial Carcinoma Diagnosed Incident Population in Japan
5.8.3 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Japan
5.8.4 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Japan
5.8.5 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Japan
5.8.6 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Japan
5.8.7 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Japan
5.8.8 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Japan

6 Appendix

7 Report Methodology

8 Capabilities

9 Disclaimer

10 About the Publisher

Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll